Collplant Biotechnologies Ltd (CLGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) has a cash flow conversion efficiency ratio of -0.309x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.88 Million) by net assets ($9.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Collplant Biotechnologies Ltd (CLGN) market capitalisation for the company's overall valuation and market capitalisation.
Collplant Biotechnologies Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Collplant Biotechnologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Collplant Biotechnologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collplant Biotechnologies Ltd ranked by their cash flow conversion efficiency. Explore Collplant Biotechnologies Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BTM Resources Bhd
KLSE:7188
|
-0.033x |
|
Banaras Beads Limited
NSE:BANARBEADS
|
-0.026x |
|
Dovre Group Plc
HE:DOV1V
|
-0.559x |
|
Lite Access Technologies Inc
V:LTE
|
1.235x |
|
Torr Metals Inc
V:TMET
|
-0.067x |
|
Coloured Ties Capital Inc
V:TIE
|
-0.031x |
|
Merchavia Holdings and Investments Ltd
TA:MRHL
|
-0.050x |
|
Asuransi Kresna Mitra Tbk PT
JK:ASMI
|
-0.047x |
Annual Cash Flow Conversion Efficiency for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Collplant Biotechnologies Ltd from 2012 to 2024. View current stock price of Collplant Biotechnologies Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.46 Million | $-14.09 Million | -1.047x | -973.53% |
| 2023-12-31 | $28.34 Million | $-2.76 Million | -0.097x | +77.02% |
| 2022-12-31 | $32.28 Million | $-13.70 Million | -0.424x | -865.55% |
| 2021-12-31 | $45.12 Million | $2.50 Million | 0.055x | +105.58% |
| 2020-12-31 | $4.48 Million | $-4.45 Million | -0.994x | +28.73% |
| 2019-12-31 | $4.09 Million | $-5.70 Million | -1.395x | -445.61% |
| 2018-12-31 | $4.76 Million | $-1.22 Million | -0.256x | +86.54% |
| 2017-12-31 | $2.61 Million | $-4.97 Million | -1.900x | +49.26% |
| 2016-12-31 | $1.34 Million | $-5.02 Million | -3.745x | -152.18% |
| 2015-12-31 | $2.51 Million | $-3.72 Million | -1.485x | -64.13% |
| 2014-12-31 | $3.68 Million | $-3.33 Million | -0.905x | -84.26% |
| 2013-12-31 | $7.78 Million | $-3.82 Million | -0.491x | +46.58% |
| 2012-12-31 | $4.20 Million | $-3.86 Million | -0.919x | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more